Document is current
Any future updates will be listed below
-
Authors
Hansildaar, Romy
van Velzen, Max
van der Vossen, Eduard W. J.
Kramer, Gertjan
Nurmohamed, Michael T.
Levels, Johannes H. M.
- License Information
-
More Information
Article History
Received: 22 August 2024
Accepted: 26 March 2025
First Online: 11 April 2025
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and received approval by the local medical ethics committee of the Slotervaart Hospital in Amsterdam, Netherlands. Furthermore, all patients provided written informed consent for this Rheumatology Registry which is an observational daily clinical practice inception cohort. It was initiated with the objective of capturing long-term data from patients using biologicals and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in inflammatory arthritis. This registry was started in 2004, and comprises RA, PsA and AS patients starting on a new b/tsDMARDs therapy. (NL59549.048.16).
: The authors declare no competing interests.
